Published in Cancer Res on October 01, 2008
A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell (2011) 1.86
miRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways. Cancer Res (2010) 1.54
PAK1 as a therapeutic target. Expert Opin Ther Targets (2010) 1.48
PAK signaling in cancer. Cell Logist (2012) 1.27
Development of small-molecule inhibitors of the group I p21-activated kinases, emerging therapeutic targets in cancer. Biochem Pharmacol (2010) 1.24
FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas. J Biol Chem (2013) 1.09
Group I p21-activated kinases (PAKs) promote tumor cell proliferation and survival through the AKT1 and Raf-MAPK pathways. Mol Cancer Res (2012) 1.06
P21 activated kinases: structure, regulation, and functions. Small GTPases (2014) 1.06
Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways. Neoplasia (2011) 1.02
miRNA signature of schwannomas: possible role(s) of "tumor suppressor" miRNAs in benign tumors. Oncotarget (2011) 1.01
p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. PLoS One (2010) 0.97
Group I Paks as therapeutic targets in NF2-deficient meningioma. Oncotarget (2015) 0.94
Rac1 controls Schwann cell myelination through cAMP and NF2/merlin. J Neurosci (2012) 0.94
LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2. Oncogene (2013) 0.92
Do PAKs make good drug targets? F1000 Biol Rep (2010) 0.91
The molecular biology of vestibular schwannomas and its association with hearing loss: a review. Genet Res Int (2012) 0.90
Optimizing biologically targeted clinical trials for neurofibromatosis. Expert Opin Investig Drugs (2013) 0.88
Contribution of persistent C-Jun N-terminal kinase activity to the survival of human vestibular schwannoma cells by suppression of accumulation of mitochondrial superoxides. Neuro Oncol (2011) 0.87
NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition. Cancer Discov (2015) 0.86
Recent advances in the development of p21-activated kinase inhibitors. Cell Logist (2012) 0.85
Paracrine signalling in colorectal liver metastases involving tumor cell-derived PDGF-C and hepatic stellate cell-derived PAK-2. Clin Exp Metastasis (2012) 0.83
EphB2 receptor forward signaling controls cortical growth cone collapse via Nck and Pak. Mol Cell Neurosci (2012) 0.83
An APPL1/Akt signaling complex regulates dendritic spine and synapse formation in hippocampal neurons. Mol Cell Neurosci (2011) 0.83
p75NTR is highly expressed in vestibular schwannomas and promotes cell survival by activating nuclear transcription factor κB. Glia (2014) 0.83
Development of p21 activated kinase-targeted multikinase inhibitors that inhibit thyroid cancer cell migration. J Clin Endocrinol Metab (2013) 0.81
A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. Oncotarget (2015) 0.79
Effects of p21-activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells. Oncogene (2015) 0.79
P21-activated kinase in inflammatory and cardiovascular disease. Cell Signal (2014) 0.78
Cdc42 regulates Schwann cell radial sorting and myelin sheath folding through NF2/merlin-dependent and independent signaling. Glia (2013) 0.78
ADP-ribosylation factor 6 (ARF6) bidirectionally regulates dendritic spine formation depending on neuronal maturation and activity. J Biol Chem (2015) 0.77
p21-activated kinase 3 (PAK3) is an AP-1 regulated gene contributing to actin organisation and migration of transformed fibroblasts. PLoS One (2013) 0.77
A splicing variant of Merlin promotes metastasis in hepatocellular carcinoma. Nat Commun (2015) 0.76
Neurofibromatosis type 2 protein, NF2: an uncoventional cell cycle regulator. Anticancer Res (2013) 0.76
Inhibiting p21-Activated Kinase Induces Cell Death in Vestibular Schwannoma and Meningioma via Mitotic Catastrophe. Otol Neurotol (2017) 0.75
Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1. Oncotarget (2016) 0.75
P14ARF deficiency and its correlation with overexpression of p53/MDM2 in sporadic vestibular schwannomas. Eur Arch Otorhinolaryngol (2014) 0.75
A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet (2003) 12.16
The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell (2001) 2.89
Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J Biol Chem (2000) 2.51
Regulation of anchorage-dependent signal transduction by protein kinase A and p21-activated kinase. Nat Cell Biol (2000) 2.37
Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell (2003) 2.23
Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase. Nature (2006) 2.15
p21-activated kinase links Rac/Cdc42 signaling to merlin. J Biol Chem (2001) 2.05
The mechanism of PAK activation. Autophosphorylation events in both regulatory and kinase domains control activity. J Biol Chem (2001) 1.96
Kinase-deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts. Mol Cell Biol (1997) 1.94
A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor. Cancer J (2004) 1.85
Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J Biol Chem (2002) 1.82
Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res (2007) 1.71
The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol (2005) 1.60
Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells. Hum Mol Genet (2003) 1.47
Conformational switch and role of phosphorylation in PAK activation. Mol Cell Biol (2001) 1.37
In vivo application of RNA interference: from functional genomics to therapeutics. Adv Genet (2005) 1.30
Cyclic AMP-dependent protein kinase phosphorylates merlin at serine 518 independently of p21-activated kinase and promotes merlin-ezrin heterodimerization. J Biol Chem (2004) 1.30
The genetic and molecular pathogenesis of NF1 and NF2. Semin Pediatr Neurol (2006) 1.24
Cellular transformation by a FERM domain mutant of the Nf2 tumor suppressor gene. Oncogene (2002) 1.23
Temporal control of Rac in Schwann cell-axon interaction is disrupted in NF2-mutant schwannoma cells. J Neurosci (2006) 1.17
Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res (2003) 15.74
RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell (2007) 8.71
MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks. Cell (2005) 8.39
The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell (2003) 7.04
Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates. Science (2003) 6.97
Systematic discovery of in vivo phosphorylation networks. Cell (2007) 6.94
BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science (2003) 6.88
The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science (2011) 6.75
Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell (2012) 5.92
TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science (2005) 5.56
A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis. Science (2005) 4.75
Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature (2008) 4.33
Cohesins localize with CTCF at the KSHV latency control region and at cellular c-myc and H19/Igf2 insulators. EMBO J (2008) 4.28
p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell (2007) 4.01
Linear motif atlas for phosphorylation-dependent signaling. Sci Signal (2008) 3.77
MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol Cell (2005) 3.48
TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat Cell Biol (2008) 3.44
Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer. Nat Struct Mol Biol (2004) 3.26
Data-driven modelling of signal-transduction networks. Nat Rev Mol Cell Biol (2006) 3.18
Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol (2009) 3.15
Hem-1 complexes are essential for Rac activation, actin polymerization, and myosin regulation during neutrophil chemotaxis. PLoS Biol (2006) 3.01
Chemical genetic screen for AMPKα2 substrates uncovers a network of proteins involved in mitosis. Mol Cell (2011) 2.99
14-3-3sigma controls mitotic translation to facilitate cytokinesis. Nature (2007) 2.98
14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. J Cell Biol (2002) 2.97
Lamellipodin, an Ena/VASP ligand, is implicated in the regulation of lamellipodial dynamics. Dev Cell (2004) 2.96
Natural-like function in artificial WW domains. Nature (2005) 2.76
Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res (2009) 2.74
Structure and function of Polo-like kinases. Oncogene (2005) 2.72
mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science (2013) 2.71
NetworKIN: a resource for exploring cellular phosphorylation networks. Nucleic Acids Res (2007) 2.69
Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest (2009) 2.66
The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev (2009) 2.56
Proteomic screen defines the Polo-box domain interactome and identifies Rock2 as a Plk1 substrate. EMBO J (2007) 2.48
Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop. Cell Cycle (2011) 2.46
The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature (2013) 2.46
Structural determinants of 14-3-3 binding specificities and regulation of subcellular localization of 14-3-3-ligand complexes: a comparison of the X-ray crystal structures of all human 14-3-3 isoforms. Semin Cancer Biol (2006) 2.42
Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell (2003) 2.23
A structural basis for 14-3-3sigma functional specificity. J Biol Chem (2005) 2.20
The transcriptional co-activator TAZ interacts differentially with transcriptional enhancer factor-1 (TEF-1) family members. Biochem J (2005) 2.15
Molecular basis for the recognition of phosphorylated and phosphoacetylated histone h3 by 14-3-3. Mol Cell (2005) 2.10
The phosphoinositide-binding protein p40phox activates the NADPH oxidase during FcgammaIIA receptor-induced phagocytosis. J Exp Med (2006) 2.03
Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2. Mol Cell (2002) 1.99
TAZ interacts with TTF-1 and regulates expression of surfactant protein-C. J Biol Chem (2004) 1.98
A mitotic phosphorylation feedback network connects Cdk1, Plk1, 53BP1, and Chk2 to inactivate the G(2)/M DNA damage checkpoint. PLoS Biol (2010) 1.90
Polo-like kinase 1 creates the tension-sensing 3F3/2 phosphoepitope and modulates the association of spindle-checkpoint proteins at kinetochores. Curr Biol (2005) 1.88
TAZ promotes PC2 degradation through a SCFbeta-Trcp E3 ligase complex. Mol Cell Biol (2007) 1.86
A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell (2011) 1.86
HIF-2alpha deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci U S A (2010) 1.86
Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1. Nat Struct Mol Biol (2009) 1.84
ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res (2006) 1.80
DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization. Mol Cell (2010) 1.78
Plk1 self-organization and priming phosphorylation of HsCYK-4 at the spindle midzone regulate the onset of division in human cells. PLoS Biol (2009) 1.78
TAZ: a beta-catenin-like molecule that regulates mesenchymal stem cell differentiation. Cell Cycle (2006) 1.76
Substrate specificity analysis of protein kinase complex Dbf2-Mob1 by peptide library and proteome array screening. BMC Biochem (2005) 1.74
Polo-like kinase Cdc5 controls the local activation of Rho1 to promote cytokinesis. Science (2006) 1.73
Cytoplasmic localization of tristetraprolin involves 14-3-3-dependent and -independent mechanisms. J Biol Chem (2002) 1.67
A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. Cell Rep (2013) 1.67
14-3-3 Proteins--a focus on cancer and human disease. J Mol Cell Cardiol (2004) 1.67
14-3-3 proteins, FHA domains and BRCT domains in the DNA damage response. DNA Repair (Amst) (2009) 1.66
14-3-3 proteins as signaling integration points for cell cycle control and apoptosis. Semin Cell Dev Biol (2011) 1.65
Cytokine-induced signaling networks prioritize dynamic range over signal strength. Cell (2008) 1.65
Phospho-Ser/Thr-binding domains: navigating the cell cycle and DNA damage response. Nat Rev Mol Cell Biol (2013) 1.62
Spatial exclusivity combined with positive and negative selection of phosphorylation motifs is the basis for context-dependent mitotic signaling. Sci Signal (2011) 1.62
A high-throughput quantitative multiplex kinase assay for monitoring information flow in signaling networks: application to sepsis-apoptosis. Mol Cell Proteomics (2003) 1.61
A positive feedback loop couples Ras activation and CD44 alternative splicing. Genes Dev (2006) 1.60
A novel assay system implicates PtdIns(3,4)P(2), PtdIns(3)P, and PKC delta in intracellular production of reactive oxygen species by the NADPH oxidase. Mol Cell (2003) 1.59
Proteomic identification of 14-3-3zeta as a mitogen-activated protein kinase-activated protein kinase 2 substrate: role in dimer formation and ligand binding. Mol Cell Biol (2003) 1.53
Progressive calcified tuber in a young male with tuberous sclerosis complex. Dev Med Child Neurol (2010) 1.53
14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci U S A (2012) 1.51
Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel. Nat Chem Biol (2011) 1.49
Computational approaches for analyzing information flow in biological networks. Sci Signal (2012) 1.49
IgG4-related disease and hypertrophic pachymeningitis. Medicine (Baltimore) (2013) 1.47
Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma. Cancer Res (2010) 1.45
Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle (2009) 1.44
A coupled chemical-genetic and bioinformatic approach to Polo-like kinase pathway exploration. Chem Biol (2007) 1.42
The rhoptry proteins ROP18 and ROP5 mediate Toxoplasma gondii evasion of the murine, but not the human, interferon-gamma response. PLoS Pathog (2012) 1.41
Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med (2009) 1.41
Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers. J Clin Invest (2017) 1.40
Distinct mechanisms act in concert to mediate cell cycle arrest. Proc Natl Acad Sci U S A (2009) 1.37
Case records of the Massachusetts General Hospital. Case 22-2006--a 77-year-old man with a rapidly progressive gait disorder. N Engl J Med (2006) 1.36
Systematic phosphorylation analysis of human mitotic protein complexes. Sci Signal (2011) 1.31
Clinical features of schwannomatosis: a retrospective analysis of 87 patients. Oncologist (2012) 1.27
Caged phosphopeptides reveal a temporal role for 14-3-3 in G1 arrest and S-phase checkpoint function. Nat Biotechnol (2004) 1.26
The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis. Sci Signal (2013) 1.25
Development of small-molecule inhibitors of the group I p21-activated kinases, emerging therapeutic targets in cancer. Biochem Pharmacol (2010) 1.24
Organization of myelinated axons by Caspr and Caspr2 requires the cytoskeletal adapter protein 4.1B. J Neurosci (2010) 1.24
The Polo-box domain: a molecular integrator of mitotic kinase cascades and Polo-like kinase function. Cell Cycle (2004) 1.23
Cellular transformation by a FERM domain mutant of the Nf2 tumor suppressor gene. Oncogene (2002) 1.23
Fluorescent caged phosphoserine peptides as probes to investigate phosphorylation-dependent protein associations. J Am Chem Soc (2003) 1.22
Functional dynamics of Polo-like kinase 1 at the centrosome. Mol Cell Biol (2009) 1.21
Combined experimental and computational analysis of DNA damage signaling reveals context-dependent roles for Erk in apoptosis and G1/S arrest after genotoxic stress. Mol Syst Biol (2012) 1.20
SIRT1 shows no substrate specificity in vitro. J Biol Chem (2005) 1.20
Exacerbation of cerebral radiation necrosis by bevacizumab. J Clin Oncol (2010) 1.18